Artwork
iconShare
 
Manage episode 490896561 series 2973891
Content provided by Antipodes Partners. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Antipodes Partners or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Alison Savas interviews James Rodda, Lead Portfolio Manager of the Antipodes Global SMIDs Fund, to explore why global small and mid-cap stocks (SMIDs) present powerful, under-appreciated alpha opportunities.

They unpack the valuation gap between SMIDs and large caps, and how Antipodes’ strong investment platform and industry-led research approach provides a unique edge in identifying mis-priced opportunities.
A must-listen for anyone considering allocating to global SMIDs.
Key times:
Why Antipodes launched a global SMIDs Fund: 0:45
Why investors should consider an allocation to global SMIDs: 3:00
The importance of industry-led research & discussion about investing in Roku Inc (NASDAQ: ROKU): 08:00
Antipodes gobal SMID Fund performance: 18:00
Why Brookdale Senior Living Inc (NYSE: BKD) is one of the Fund's largest positions: 24:50
Stock commentary is illustrative only. Not recommendations to buy, hold, or sell any security.

  continue reading

60 episodes